ZA923474B - Diltiazem formulation - Google Patents

Diltiazem formulation

Info

Publication number
ZA923474B
ZA923474B ZA923474A ZA923474A ZA923474B ZA 923474 B ZA923474 B ZA 923474B ZA 923474 A ZA923474 A ZA 923474A ZA 923474 A ZA923474 A ZA 923474A ZA 923474 B ZA923474 B ZA 923474B
Authority
ZA
South Africa
Prior art keywords
diltiazem
diltiazem formulation
formulation
image
blend
Prior art date
Application number
ZA923474A
Other languages
English (en)
Inventor
Dennis L Hendrickson
L Hendrickson Dennis
Dan C Dimmitt
C Dimmitt Dan
Mark S Williams
S Williams Mark
Paul F Skultety
F Skultety Paul
Michael J Baltezor
J Baltezor Michael
Original Assignee
Marion Merrell Dow Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marion Merrell Dow Inc filed Critical Marion Merrell Dow Inc
Publication of ZA923474B publication Critical patent/ZA923474B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA923474A 1991-05-20 1992-05-13 Diltiazem formulation ZA923474B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70256791A 1991-05-20 1991-05-20

Publications (1)

Publication Number Publication Date
ZA923474B true ZA923474B (en) 1993-01-27

Family

ID=24821752

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA923474A ZA923474B (en) 1991-05-20 1992-05-13 Diltiazem formulation

Country Status (17)

Country Link
EP (1) EP0514814B1 (zh)
JP (1) JP3804029B2 (zh)
KR (1) KR100244010B1 (zh)
AT (1) ATE147982T1 (zh)
AU (1) AU653223B2 (zh)
CA (1) CA2068980A1 (zh)
DE (1) DE69216910T2 (zh)
DK (1) DK0514814T3 (zh)
ES (1) ES2099764T3 (zh)
FI (1) FI922270A (zh)
GR (1) GR3022927T3 (zh)
IE (1) IE921603A1 (zh)
IL (1) IL101896A (zh)
NO (1) NO921973L (zh)
NZ (1) NZ242730A (zh)
TW (1) TW265267B (zh)
ZA (1) ZA923474B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
US7070806B2 (en) 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
JP3842815B2 (ja) * 1993-09-08 2006-11-08 ファーマシー アンド テラプティック アドバイザリー コンサルタンシー リミテッド 血管拡張剤による肝臓病および同様の症状の治療方法
US6174917B1 (en) 1993-09-08 2001-01-16 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US5854233A (en) * 1993-09-08 1998-12-29 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
FR2754710B1 (fr) * 1996-10-22 1998-12-31 Prographarm Lab Procede de preparation d'une forme pharmaceutique multiparticulaire a liberation controlee plurisequentielle
US6162463A (en) * 1997-05-01 2000-12-19 Dov Pharmaceutical Inc Extended release formulation of diltiazem hydrochloride
CA2270975C (en) 1997-07-02 2003-04-01 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
FR2771292B1 (fr) * 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
WO1999038507A1 (en) * 1998-01-30 1999-08-05 David George Le Couteur Reversal and prevention of clinically significant aspects of aging through oral use of hepatic artery vasodilator and other agents which increase hepatic oxygenation
JP4613275B2 (ja) * 1998-11-02 2011-01-12 エラン ファーマ インターナショナル，リミティド 多粒子改質放出組成物
NZ529308A (en) * 2001-04-05 2005-03-24 Collagenex Pharm Inc Tetracycline compounds comprising a tetracycline and a controlled release agent to provide delivery at a dose below that required for antibiotic activity
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US7866376B2 (en) 2007-10-29 2011-01-11 Fu Zhun Precision Industry (Shen Zhen) Co., Ltd. Heat dissipation device with U-shaped and S-shaped heat pipes
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN114425046B (zh) * 2021-12-16 2023-10-20 南通联亚药业股份有限公司 一种盐酸地尔硫卓缓释胶囊

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
JPS6215A (ja) * 1985-02-26 1987-01-06 Fujisawa Pharmaceut Co Ltd ２−ニトロオキシメチル−６−クロロピリジンまたはそのβ−シクロデキストリン包接化合物含有持続性製剤
JPS62114910A (ja) * 1985-11-13 1987-05-26 エラン　コ−ポレ−シヨン　ピ−　エル　シ− 吸収がコントロ−ルされた医薬製剤
IT1200217B (it) * 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
DK173505B1 (da) * 1987-02-20 2001-01-15 Pharmatec Internat S R L Fremgangsmåde til fremstilling af en diltiazempellet med langsom afgivelse og anvendelse af således fremstillede pelleter t
ES2194832T3 (es) * 1987-10-16 2003-12-01 Elan Corp Plc Formulaciones de ditiazem con absorcion controlada.
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
SE8902699D0 (sv) * 1989-08-09 1989-08-09 Lejus Medical Ab Diltiazem containing pharmaceutical compositios

Also Published As

Publication number Publication date
IE921603A1 (en) 1992-12-02
KR920021150A (ko) 1992-12-18
ATE147982T1 (de) 1997-02-15
GR3022927T3 (en) 1997-06-30
FI922270A (fi) 1992-11-21
IL101896A (en) 1996-08-04
FI922270A0 (fi) 1992-05-19
EP0514814B1 (en) 1997-01-22
CA2068980A1 (en) 1992-11-21
ES2099764T3 (es) 1997-06-01
AU653223B2 (en) 1994-09-22
DK0514814T3 (da) 1997-02-10
EP0514814A1 (en) 1992-11-25
DE69216910D1 (de) 1997-03-06
NO921973L (no) 1992-11-23
JP3804029B2 (ja) 2006-08-02
AU1632692A (en) 1992-11-26
KR100244010B1 (ko) 2000-03-02
DE69216910T2 (de) 1997-05-22
NO921973D0 (no) 1992-05-19
JPH05178747A (ja) 1993-07-20
NZ242730A (en) 1994-09-27
IL101896A0 (en) 1992-12-30
TW265267B (zh) 1995-12-11

Similar Documents

Publication Publication Date Title
TW265267B (zh)
ZA919629B (en) Novel 4-arylpiperazines and 4-arylpiperidines
KR100257086B1 (en) Projection type liquidcrystal projector
AU1522892A (en) Continuous mixing of elastomeric compounds
AU1004992A (en) Primary cementing
PH30666A (en) Diltiazem pharmaceutical spheroid formulation
ZA925128B (en) Pyrrolidine derivatives,their preparation and medicaments containing them
DE69329992D1 (de) Farbbildprojektor
AU1752992A (en) Light projection apparatus
AU1513092A (en) Dehalogenation of organohalogen-containing compounds
AU2968292A (en) Illumination of displays
IL87490A0 (en) Pharmaceutical compositions containing 2-pyrimidinyl-1-piperazine derivatives for the treatment of alcoholism
GB9124733D0 (en) Derivatives of poly-4-amino-2-carboxy-1-methyl compounds
EP0508239A3 (en) Recessed light projector
AU2574892A (en) Liquid colored toner compositions
GB2263185B (en) Colour LCD system of projection type
GR1002598B (el) Παραγωγα επι-επιβατιδινης.
AU1027792A (en) A pour-on formulation for the administration of anthelmintics
EP0508157A3 (en) Light projector
GB9121205D0 (en) Derivatives of poly-5-amino-3-carboxy-1-methyl compounds
HU9402237D0 (en) Use of benzene-sulfonyl-indol derivatives for producing pharmaceutical compositions
AU1455192A (en) Purified lam and synthetic analogs thereof
NZ243690A (en) Process for the preparation of 13-<alpha>-cinnamoylbaccatine iii derivatives
AU7721594A (en) Analogs of hirudin
IT1255094B (it) Derivati tetraidropiridoimidazolonici come agenti nootropici